The Relative Persistency and Effectiveness of Guselkumab in the Real-World

In this episode of RhAPPcast, Amanda Mixon, PA-C, President of RhAPP, sits down with Kyle George, PA-C, to explore the real-world impact of Guselkumab in Psoriatic Arthritis (PsA) management. As a leading IL-23 inhibitor, Guselkumab offers durable efficacy, strong persistence, and a favorable safety profile, making it a key option for biologic-naïve patients and those with TNF inhibitor failure.

Clinical trials like VOYAGE, NAVIGATE, ECLIPSE, and DISCOVER highlight its effectiveness in improving joint and skin symptoms, while real-world data from the CorEvitas PsA and SpA Registry shows 72% of patients remain on Guselkumab after 12 months, compared to just 44% on TNF inhibitors. Kyle shares patient cases that demonstrate how IL-23 inhibition is reshaping PsA treatment, offering comprehensive disease control, improved adherence with its once-every-eight-weeks dosing schedule, and a monotherapy option without methotrexate.

This conversation is essential for rheumatology providers, NPs, and PAs looking to optimize PsA treatment strategies. Learn why IL-23 inhibitors are gaining momentum and how real-world evidence supports Guselkumab’s long-term efficacy and safety.

For expert insights on PsA management and IL-23 inhibitors, visit RhAPP.org or explore the RhAPP ACE App for the latest in rheumatology education.